Viewray (VRAY) Now Covered by Analysts at B. Riley

Analysts at B. Riley initiated coverage on shares of Viewray (NASDAQ:VRAY) in a report released on Thursday, Marketbeat Ratings reports. The firm set a “buy” rating and a $13.50 price target on the stock. B. Riley’s price target points to a potential upside of 71.32% from the company’s current price.

Several other research firms have also issued reports on VRAY. Mizuho reissued a “buy” rating and set a $12.00 target price on shares of Viewray in a research note on Wednesday, October 25th. BidaskClub downgraded shares of Viewray from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Viewray in a report on Friday, January 5th. Northland Securities reaffirmed a “buy” rating and set a $10.00 price target on shares of Viewray in a report on Friday, November 17th. Finally, ValuEngine downgraded shares of Viewray from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $11.58.

Viewray (NASDAQ VRAY) traded down $0.29 during trading on Thursday, hitting $7.88. 754,347 shares of the company’s stock were exchanged, compared to its average volume of 746,299. Viewray has a 12-month low of $4.40 and a 12-month high of $10.64. The company has a market capitalization of $532.24, a price-to-earnings ratio of -7.23 and a beta of 14.36. The company has a debt-to-equity ratio of -1.67, a current ratio of 1.59 and a quick ratio of 1.20.

Viewray (NASDAQ:VRAY) last issued its quarterly earnings data on Monday, November 13th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The company had revenue of $12.20 million for the quarter, compared to the consensus estimate of $18.63 million. Viewray’s revenue was up 2950.0% on a year-over-year basis. sell-side analysts forecast that Viewray will post -1.05 earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of VRAY. Nationwide Fund Advisors grew its holdings in shares of Viewray by 843.2% in the second quarter. Nationwide Fund Advisors now owns 16,543 shares of the company’s stock valued at $107,000 after purchasing an additional 14,789 shares in the last quarter. HighTower Advisors LLC lifted its holdings in shares of Viewray by 5.0% in the 2nd quarter. HighTower Advisors LLC now owns 21,000 shares of the company’s stock valued at $135,000 after buying an additional 1,000 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in shares of Viewray in the 2nd quarter valued at approximately $159,000. Thompson Siegel & Walmsley LLC acquired a new stake in shares of Viewray in the 3rd quarter valued at approximately $164,000. Finally, Rhumbline Advisers acquired a new stake in shares of Viewray in the 2nd quarter valued at approximately $193,000. 50.52% of the stock is owned by institutional investors and hedge funds.

WARNING: This article was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/02/11/viewray-vray-now-covered-by-analysts-at-b-riley.html.

Viewray Company Profile

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Analyst Recommendations for Viewray (NASDAQ:VRAY)

Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply